skip to Main Content

Ongoing Research Pushes Precision Oncology Mindset in Gastrointestinal Cancers

Newsfeed image, light gray text on dark gray background
With highly anticipated data across gastrointestinal (GI) cancers expected to read out in the near future—including the phase 3 NAPOLI-3 (NCT04083235) and HIMALAYA (NCT03298451) trials in pancreatic cancer and hepatocellular carcinoma (HCC), respectively— researchers are already gearing up for future research efforts that will continue to put precision oncology at the forefront of treatment, according to E. Gabriela Chiorean, MD.

“Molecular profiling [are crucial aspects] of care for every patient with any solid tumor that has advanced-stage, metastatic disease,” said Chiorean in an interview during an Institutional Perspectives in Cancer webinar on gastrointestinal cancers. “The more [we know] about the cancer, the more treatment options there are. There is exciting research moving forward with immune checkpoint inhibitors, especially in liver cancers and neuroendocrine cancers, but also many new targeted therapies, and new chemotherapies in pancreatic cancer and other tumors.” Read more . . . 

Back To Top